Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Drug Therapeutics: Therapeutic Proteins' returned 1055 results - Page 1 of 53   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Therapeutic Proteins to 2014   Greystone Associates, Nov 2010 to the bioavailability targets and pharmacokinetic profiles of specific drug therapies. Highlights - Analyzes approved therapeutic protein products and pipeline candidates and assesses the market potential for existing Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market   GBI Research, Sep 2011, Pages: 142 growth rate in the coming years. On the other hand, the introduction of new oral therapeutic proteins will increase the patient pool due to better drug compliance. Even though the competition from gene Drug Reconstitution at the Point-of-Care: Therapeutic Markets, Technologies, Strategies, and Prospects   Greystone Associates, Jan 2012 The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated Injectable Drug Delivery: Drugs, Devices, Targets, Therapeutics and Forecasts   Greystone Associates, Jan 2012 in response to safety and economic challenges posed by recombinant protein drugs, while administration of injectables has moved increasingly from practitioner offices and healthcare facilities to patient homes Point-of-Delivery Drug Reconstitution Systems   Greystone Associates, Jan 2011 The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated Proteomics - Technologies, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 607 metalloproteases as drug targets PDZ proteins as drug targets Proteasome as drug target Serine hydrolases as drug targets Targeting mTOR signaling pathway Targeting caspase-8 for anticancer therapeutics Drug Self-Administration Markets to 2016   Greystone Associates, Jan 2012 While alternative methods for delivering therapeutics to patients have had some notable successes, most drugs continue to be delivered orally. Because they cannot tolerate the first-pass metabolism The Fourth Wave: A New Generation of Protein-Based Therapeutics   Decision Resources, Inc., Aug 2006, Pages: 22 protein and MAb therapeutics into next-generation drugs. What opportunities are being pursued for improving protein therapeutics? How will next-generation drugs improve upon their predecessors? Targeting Next-Generation Protein and Peptide Therapeutics   Business Insights, Aug 2011, Pages: 192 The utility of mAb therapeutics is balanced by many drawbacks: they are expensive to produce, have poor tissue penetration, can only be used to target cell-surface proteins or soluble proteins Peptide and Protein Delivery   Elsevier Science and Technology, May 2011, Pages: 380 The growing area of peptide and protein therapeutics research is of paramount importance to medical application and advancement. A needed reference for entry level researchers and researchers G-Protein Coupled Receptors (GPCRs) - Global Strategic Business Report   Global Industry Analysts, Inc., Feb 2011, Pages: 299 Illustrative Examples of Currently Available Pharmaceutical Drugs Targeting GPCRs 4 Untapped Pharmacological Potential of GPCRs Ignites Interest 5 Popular Types of GPCRs of Therapeutic Interest Currently Therapeutic Protein Pipeline Database: 1-Year Subscription   La Merie, Feb 2012 Subscription to the Therapeutic Protein Pipeline Database provides online access to more than 1,700 project entries for therapeutic proteins on the market and in research & development. Each project Pursuing Next-Generation Therapeutic Antibodies as the Next Source of Blockbuster Drugs   Decision Resources, Inc., June 2011 Next-generation antibodies promise to create not just me-too products of existing protein therapeutics but me-better products through protein engineering. The success of monoclonal antibody (MAb Diabetic Nephropathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017   GlobalData, April 2011, Pages: 72 in this market in the future. GlobalData holds profiles of all of the above companies as they possess important pipeline drugs in early and late stage development for DN therapeutics. The existing market landscape remains Triple Analysis: Breast Cancer, Pancreatic Cancer and Protein Kinase Inhibitors   Bioseeker, April 2010, Pages: 2965 Therapeutic Pipeline? (200 Drug Target Strategies and 409 Drugs) 337-407 8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Drugs in Oncology by Compound Type (7 Compound Strategies) 408 Triple Analysis: Breast Cancer, Apoptosis and Protein Kinase Inhibitors   Bioseeker, Dec 2011, Pages: 3972 are the Drug Target Profiles Identified in the Cancer Protein Kinase Therapeutic Pipeline? (200 Drug Target Strategies and 409 Drugs) 337-407 8 Compound Strategies at Work: Competitive Benchmarking of Protein Triple Analysis: Pancreatic Cancer, Apoptosis and Protein Kinase Inhibitors   Bioseeker, Dec 2011, Pages: 3669 are the Drug Target Profiles Identified in the Cancer Protein Kinase Therapeutic Pipeline? (200 Drug Target Strategies and 409 Drugs) 337-407 8 Compound Strategies at Work: Competitive Benchmarking of Protein Triple Analysis: Breast Cancer, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, Jan 2012, Pages: 4059 Number of Pages: 1,704 Part III: Protein Kinase Inhibitors 5.1 The Scope of this Report 30 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (133 Drug Targets Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, Jan 2012, Pages: 3756 on Investment (133 Drug Targets) 36-336 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Protein Kinase Therapeutic Pipeline? (200 Drug Nanobiotechnology Applications, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 772 to RBCs Self-assembling nanoparticles for intracellular drug delivery Trojan nanoparticles Therapeutic protein delivery from nanoparticle-protein complexes Triggered release of drugs from nanoparticles Results:  First -   Prev -   1 -   2 -   3 -   4 -   5 -   6 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets1    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network